Contract pharmacy, explained without the acronyms.
An arrangement that lets a covered entity extend 340B dispensing to pharmacies it does not own. It expanded enormously between 2010 and 2022, and it has been contracting under manufacturer restrictions ever since.
At a glance
- 01Locations nationally
- ~32,000–33,000
- 02Average per entity
- ~20
- 03Manufacturers restricting
- 36+
- 04States with protection laws
- 18+
What a contract pharmacy actually is
Many covered entities have no pharmacy of their own, or have one that cannot reach every patient. A contract pharmacy arrangement lets the entity use an outside pharmacy — usually a retail chain, an independent pharmacy or a specialty pharmacy — to dispense 340B drugs to its eligible patients.
The pharmacy acts as an agent of the covered entity. The entity retains title to the drug, remains responsible for compliance, and pays the pharmacy a dispensing fee. The arrangement must be documented in a written agreement and registered in OPAIS.
Ship-to bill-to
The structural mechanism is called ship-to bill-to. The drug is shipped to the pharmacy but billed to the covered entity, so ownership never transfers to the pharmacy. Getting this structure wrong undermines the legitimacy of every dispense at that location, which is why it is one of the first things an auditor examines.
Oversight is not delegable
The covered entity remains responsible for compliance at every contract pharmacy. Using a third-party administrator to process the transactions does not transfer that responsibility. HRSA expects to see documented oversight — self-audits, reconciliation records, corrective actions — for each arrangement, not a statement that a vendor handles it.
The agreement is only half the picture.
A signed contract pharmacy agreement is where oversight starts, not where it ends — ongoing reconciliation is what actually prevents the finding.
What changed after 2020
Beginning in 2020, drug manufacturers started limiting 340B pricing on drugs dispensed through contract pharmacies. More than thirty manufacturers now impose some form of restriction, and the specifics differ substantially between them.
Litigation has produced mixed outcomes across circuits, and more than eighteen states have enacted contract pharmacy protection laws — several of which are themselves being challenged. The position is genuinely unsettled and changes several times a year.
- Full denial of 340B pricing on contract pharmacy dispenses
- A single designated contract pharmacy permitted per entity
- Claims-level data submission required through a designated platform
- Conditions that vary by entity type — grantees sometimes treated differently from hospitals
- Attestation that the entity has no in-house pharmacy capability
- Exceptions where a state protection law applies and is not enjoined
We maintain a restriction matrix and re-verify state law status before advising, rather than working from a static list.
Contract pharmacy — common questions
01Does the 340B statute authorize contract pharmacy?
The statute does not explicitly address it. HRSA guidance from 1996 permitted a single contract pharmacy, and 2010 guidance permitted multiple arrangements. The absence of explicit statutory language is central to the current litigation and to reform proposals.
02How many contract pharmacies can we have?
HRSA guidance does not set a numeric limit, and some large entities have hundreds. The practical limit is how many you can genuinely oversee with documented evidence — because oversight obligation, not arrangement count, is what auditors test.
03What is a designated contract pharmacy?
Where a manufacturer restricts contract pharmacy access, some permit the entity to designate one location that will still receive 340B pricing. Election processes and deadlines differ by manufacturer, and missing a deadline can mean losing access for a full period.
04Do state protection laws override manufacturer restrictions?
That is exactly what is being litigated, and outcomes have varied. More than eighteen states have enacted protections, several are subject to legal challenge, and status changes. Advice needs to be state-specific and current rather than general.
Marked up with FAQPage schema for search and AI-answer eligibility.
Next step
Do you know your restriction exposure by drug and location?
Most entities have a general sense. Few have a number.